Rigel Pharmaceuticals (RIGL) Work In Process (2018 - 2026)

Rigel Pharmaceuticals has reported Work In Process for 9 years, with the latest figure at $6.2 million in Q1 2026.

• For the quarter ending Q1 2026, Work In Process rose 462.69% year-over-year to $6.2 million; the trailing twelve-month figure through Mar 2026 stood at $6.2 million (up 462.69% YoY), and the FY2025 full-year result was $3.9 million, up 218.92% from the prior year.
• Work In Process for Q1 2026 stood at $6.2 million, up from $3.9 million in the prior quarter.
• The five-year high for Work In Process was $6.2 million in Q1 2026, with the low at $572000.0 in Q2 2022.
• Average Work In Process over 5 years is $2.8 million, with a median of $2.0 million recorded in 2023.
• Year-over-year, Work In Process jumped 1541.36% in 2022 and sank 78.38% in 2025.
• Tracing RIGL's Work In Process over 5 years: stood at $2.7 million in 2022, then fell by 29.45% to $1.9 million in 2023, then plunged by 34.65% to $1.2 million in 2024, then surged by 218.92% to $3.9 million in 2025, then soared by 59.31% to $6.2 million in 2026.
• The last three Work In Process figures came in at $6.2 million (Q1 2026), $3.9 million (Q4 2025), and $5.5 million (Q3 2025), per Business Quant data.

Peer Comparison